Rate of Kidney Function Decline in Older Adults: A Comparison Using Creatinine and Cystatin C

Background/Aims: The aim of this study was to determine the decline in the estimated glomerular filtration rate (eGFR) in elderly persons and to compare estimates based on creatinine and cystatin C. Methods: In the Cardiovascular Health Study, GFR changes in an elderly cohort were estimated from serum creatinine and cystatin C measured at baseline, year 3 and year 7 in 4,380 participants (age 72 ± 5 years at entry). Outcomes were mean eGFR decline, incident chronic kidney disease (CKD) and rapid decline in eGFR (annual loss >3 ml/min/1.73 m2). Results: Mean annual eGFR loss as estimated from creatinine was 0.4 ± 3.6 ml/min/1.73 m2, with 16% of the participants experiencing a rapid decline. Mean eGFR loss as estimated from cystatin C was 1.8 ± 2.6, with 25% of the participants experiencing a rapid decline (p < 0.001 for both). Among participants without baseline CKD, incident CKD was detected at year 7 in 10% (n = 263) using creatinine and 19% (n = 544) using cystatin C (p < 0.001). Increasing age was the strongest predictor of rapid decline; adjusted odds ratios were 1.38 (1.16–1.65), 1.62 (1.31–1.99) and 2.96 (2.28–3.84) for participants aged 70–74, 75–79 and 80+ at baseline, compared with those aged 65–69. Conclusion: In elderly persons, cystatin C estimated substantially larger declines in kidney function than creatinine did. Defining the optimal measurement of kidney function in elderly persons should be a high priority for future research.

[1]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[2]  Lawrence Appel,et al.  Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[3]  B. Psaty,et al.  Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. , 2005, JAMA.

[4]  D. Siscovick,et al.  Rapid kidney function decline and mortality risk in older adults. , 2008, Archives of internal medicine.

[5]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Z. Šidák.  Rectangular Confidence Regions for the Means of Multivariate Normal Distributions , 1967 .

[7]  M. Tonelli,et al.  Progression of kidney dysfunction in the community-dwelling elderly. , 2006, Kidney international.

[8]  E. Randers,et al.  Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. , 1999, Scandinavian journal of clinical and laboratory investigation.

[9]  H. Brenner,et al.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. , 2005, Clinical chemistry.

[10]  M. Shlipak,et al.  Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study , 2006, Circulation.

[11]  C. Schmid,et al.  Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  R. Kronmal,et al.  The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.

[13]  L. Fried,et al.  Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. , 1993, Annals of epidemiology.

[14]  W. G. Walker.  Hypertension-related renal injury: a major contributor to end-stage renal disease. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  Charles E. McCulloch,et al.  CHRONIC KIDNEY DISEASE AND THE RISKS OF DEATH, CARDIOVASCULAR EVENTS, AND HOSPITALIZATION , 2004 .

[16]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[17]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[18]  M. Blaufox,et al.  Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. , 1989, Hypertension.

[19]  L. Fried,et al.  Cystatin C Concentration as a Risk Factor for Heart Failure in Older Adults , 2005, Annals of Internal Medicine.

[20]  N W Shock,et al.  Longitudinal Studies on the Rate of Decline in Renal Function with Age , 1985, Journal of the American Geriatrics Society.

[21]  L. Hansson,et al.  Cystatin C: A Novel Predictor of Outcome in Suspected or Confirmed Non–ST-Elevation Acute Coronary Syndrome , 2004, Circulation.

[22]  W. McClellan,et al.  Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[23]  B. Eriksen,et al.  The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. , 2006, Kidney international.

[24]  S. Cummings,et al.  Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  M. Shlipak,et al.  Cardiovascular Mortality Risk in Chronic Kidney Disease: Comparison of Traditional and Novel Risk Factors , 2005 .

[26]  R. Klein,et al.  The 10-year incidence of renal insufficiency in people with type 1 diabetes. , 1999, Diabetes care.

[27]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[28]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  J. Weinberg,et al.  Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. , 2007, Journal of the American Society of Nephrology : JASN.

[30]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.